|Videos|November 9, 2020
REL-1017: A New Treatment in the Works for Depression
Author(s)Maurizio Fava, MD
Learn about REL-1017, the medication that has the potential to be the first single agent oral NMDAR antagonist for the adjunctive treatment of depression.
Advertisement
Relmada Therapeutics just completed their phase II adjunctive major depressive disorder trial for their new medication dextromethadone (REL-1017), where they observed statistically significant anti-depressant effects, a favorable safety profile, and favorable tolerability. Maurizio Fava, MD, discusses the results and need-to-know information for REL-1017.
Dr Fava is chief of psychiatry at Massachusetts General Hospital and director of the division of clinical research for Massachusetts General Research Institute.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder
2
FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults
3
How Can Sleep Disruption Trigger Mood Episodes?
4
Evaluating Transdermal Asenapine in Schizophrenia
5